Natco Pharma stock surged over 6% on Friday after the Delhi High Court dismissed Roche's appeal, clearing the way for the Hyderabad-based company to launch an affordable generic version of Risdiplam. A key drug used in treating spinal muscular atrophy (SMA). The ruling marks a major victory for access to affordable healthcare in India.